These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 12168892

  • 1. Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast.
    Lebrecht A, Buchmann J, Hefler L, Lampe D, Koelbl H.
    Anticancer Res; 2002; 22(3):1909-11. PubMed ID: 12168892
    [Abstract] [Full Text] [Related]

  • 2. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K, Wang J, Bourne P, Yang Q, Gao AC, Lyman G, Tang P.
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [Abstract] [Full Text] [Related]

  • 3. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR, Abd-Elwahed SR, Abdulwahed AR.
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [Abstract] [Full Text] [Related]

  • 4. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V, Sotiropoulou E, Valsamaki P, Tsaroucha A, Sotiropoulou M, Ptohis N, Stipsanelli A, Dimitrakakis K, Marinopoulos S, Tsiouris S, Antsaklis A.
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [Abstract] [Full Text] [Related]

  • 5. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG, Uner A, Yildiz I, Guler G, Takahashi M.
    Pathol Res Pract; 2009 Oct; 205(6):403-8. PubMed ID: 19232840
    [Abstract] [Full Text] [Related]

  • 6. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B.
    Anticancer Res; 2005 Oct; 25(3A):1719-23. PubMed ID: 16033090
    [Abstract] [Full Text] [Related]

  • 7. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ.
    Barnes NL, Boland GP, Davenport A, Knox WF, Bundred NJ.
    Br J Surg; 2005 Apr; 92(4):429-34. PubMed ID: 15736216
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Bircan S, Kapucuoglu N, Baspinar S, Inan G, Candir O.
    Pathol Res Pract; 2006 Apr; 202(8):569-76. PubMed ID: 16828238
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
    Shen KL, Yang LS, Hsieh HF, Chen CJ, Yu JC, Tsai NM, Harn HJ.
    J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO, Corte MD, Junquera S, Bongera M, Rodriguez JC, Vizoso FJ.
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E.
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [Abstract] [Full Text] [Related]

  • 16. [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast].
    Zhou L, Wang Y, Song X, Du JW, Pei F, Huang LP, Wang WY, Liu ZB, Pan RQ.
    Zhonghua Yi Xue Za Zhi; 2005 Nov 16; 85(43):3035-8. PubMed ID: 16324401
    [Abstract] [Full Text] [Related]

  • 17. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
    Diallo R, Rody A, Jackisch C, Ting E, Schaefer KL, Kissler S, Karn T, Geddert H, Engels K, Kaufmann M, Gabbert HE, Shroyer KR, Poremba C.
    Hum Pathol; 2006 Feb 16; 37(2):205-11. PubMed ID: 16426921
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The receptor expression pattern in ductal carcinoma in situ predicts recurrence.
    Kepple J, Henry-Tillman RS, Klimberg VS, Layeeque R, Siegel E, Westbrook K, Korourian S.
    Am J Surg; 2006 Jul 16; 192(1):68-71. PubMed ID: 16769278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.